Research progress of chimeric antigen receptor natural killer cells in hematological malignancies / 国际生物医学工程杂志

ABSTRACT

Chimeric antigen receptor natural killer cell (CAR-NK) is a new promising immunotherapy. NK cell can derive from peripheral blood cells, cord blood cells, NK-92 cell line and iPSC cells. CAR-NK cells can recognize target antigens non-specifically and are not restricted by human leukocyte antigens. Allogeneic infusion of CAR-NK cells does not cause graft-versus-host disease. It has a strong effect on primary cells of leukemia, lymphoma and multiple myeloma, thus making animal models have strong anti-tumor effect. Therefore, as a "off-the-shelf" product, CAR-NK cells have a wide range of clinical applications. In this paper, the construction of CAR-NK vector and its preliminary clinical application in hematological tumors and the challenges were reviewed.